Last Close
Feb 06  •  04:00PM ET
0.4183
Dollar change
+0.0283
Percentage change
7.26
%
Today, 6:31 PMAnticipation for upcoming Q1 earnings report fueled the intraday surge amid recent partnership momentum.
Index- P/E- EPS (ttm)-2.22 Insider Own8.40% Shs Outstand34.36M Perf Week-16.39%
Market Cap14.38M Forward P/E- EPS next Y-1.70 Insider Trans-4.03% Shs Float31.51M Perf Month-30.85%
Enterprise Value451.93M PEG- EPS next Q-0.64 Inst Own23.82% Short Float6.26% Perf Quarter-64.55%
Income-68.62M P/S0.03 EPS this Y5.28% Inst Trans-1.42% Short Ratio2.48 Perf Half Y-78.66%
Sales513.02M P/B0.11 EPS next Y14.81% ROA-8.15% Short Interest1.97M Perf YTD-25.58%
Book/sh3.96 P/C0.66 EPS next 5Y- ROE-44.78% 52W High4.51 -90.73% Perf Year-89.99%
Cash/sh0.63 P/FCF- EPS past 3/5Y46.54% -37.40% ROIC-37.54% 52W Low0.38 9.73% Perf 3Y-94.57%
Dividend Est.- EV/EBITDA21.98 Sales past 3/5Y-2.15% 53.36% Gross Margin12.68% Volatility16.27% 9.33% Perf 5Y-96.46%
Dividend TTM- EV/Sales0.88 EPS Y/Y TTM47.11% Oper. Margin-6.89% ATR (14)0.06 Perf 10Y-73.01%
Dividend Ex-Date- Quick Ratio0.23 Sales Y/Y TTM4.54% Profit Margin-13.38% RSI (14)29.63 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.35 EPS Q/Q65.74% SMA20-21.17% Beta4.19 Target Price6.00
Payout- Debt/Eq3.38 Sales Q/Q5.92% SMA50-35.12% Rel Volume0.82 Prev Close0.39
Employees2046 LT Debt/Eq0.34 EarningsFeb 09 BMO SMA200-71.97% Avg Volume797.16K Price0.42
IPONov 25, 1997 Option/ShortYes / Yes EPS/Sales Surpr.45.65% 1.87% Trades Volume651,679 Change7.26%
Date Action Analyst Rating Change Price Target Change
May-14-24Downgrade Jefferies Buy → Hold $11.50 → $3.75
Feb-09-24Upgrade Jefferies Hold → Buy $3 → $11.50
Jul-20-23Initiated Wells Fargo Overweight $9
Jan-19-23Downgrade Jefferies Buy → Hold $10 → $8
Jan-11-23Upgrade Lake Street Hold → Buy $4 → $10
Nov-18-22Downgrade Lake Street Buy → Hold $60 → $7
Oct-04-22Initiated Jefferies Buy $27
Jan-31-22Initiated Lake Street Buy $60
Sep-20-21Initiated Craig Hallum Buy $45
Feb-04-26 06:30AM
Jan-13-26 09:15AM
Dec-11-25 09:00AM
Dec-04-25 06:05PM
Dec-03-25 04:05PM
07:00AM Loading…
Nov-25-25 07:00AM
Nov-21-25 07:00AM
Nov-17-25 04:05PM
Oct-24-25 10:20AM
Oct-21-25 04:05PM
Aug-20-25 07:37AM
Aug-13-25 07:00AM
Aug-06-25 09:16PM
05:50PM
04:05PM
07:15AM Loading…
Aug-05-25 07:15AM
Jul-23-25 07:00AM
May-22-25 04:05PM
May-08-25 03:28AM
12:05AM
12:03AM
May-07-25 06:45PM
04:05PM
May-06-25 08:45AM
May-01-25 10:01AM
Apr-30-25 10:01AM
Apr-23-25 04:05PM
Feb-06-25 02:14AM
Feb-05-25 04:05PM
Jan-22-25 04:05PM
04:05PM Loading…
Dec-30-24 04:05PM
Dec-23-24 04:05PM
Dec-18-24 08:00AM
Dec-17-24 04:03PM
Dec-04-24 02:00AM
Dec-03-24 04:05PM
Dec-02-24 07:02AM
Nov-21-24 08:30AM
Nov-20-24 04:05PM
Nov-07-24 08:00AM
Oct-09-24 05:54PM
Sep-16-24 08:00AM
Aug-28-24 04:05PM
Aug-08-24 06:15PM
04:05PM
Jul-25-24 08:00AM
Jul-09-24 06:50AM
Jul-01-24 10:20AM
Jun-10-24 07:30AM
Jun-03-24 02:49PM
01:24PM
May-23-24 04:15PM
May-15-24 09:54PM
04:05PM
May-14-24 08:19AM
07:34AM
07:00AM
May-10-24 05:20AM
May-09-24 06:56PM
Apr-29-24 04:05PM
Apr-03-24 08:50AM
Apr-02-24 08:50AM
Mar-25-24 09:40AM
Mar-18-24 08:50AM
Mar-12-24 04:42PM
Mar-07-24 04:20PM
12:00PM
08:50AM
Mar-01-24 09:40AM
Feb-29-24 08:50AM
Feb-27-24 01:34PM
Feb-20-24 07:38AM
Feb-19-24 08:50AM
Feb-14-24 09:40AM
Feb-09-24 08:25AM
Feb-08-24 09:55AM
08:54AM
Feb-07-24 06:10PM
04:05PM
Jan-29-24 04:05PM
Jan-27-24 09:00AM
Dec-16-23 03:01PM
Dec-15-23 08:50AM
Dec-14-23 08:14AM
Dec-12-23 07:45AM
Dec-11-23 09:54PM
04:05PM
Dec-06-23 04:30PM
Nov-27-23 04:05PM
Nov-13-23 04:05PM
Nov-08-23 07:30AM
Nov-01-23 08:00AM
Oct-16-23 08:00AM
Aug-29-23 06:47PM
Aug-24-23 04:05PM
Aug-15-23 03:31PM
Aug-10-23 06:15PM
04:08PM
Jul-24-23 04:35PM
Jul-20-23 08:24PM
Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leasure Robert Jr.President and CEOFeb 02 '26Sale0.50113,29757,0341,273,025Feb 03 04:14 PM
Leasure Robert Jr.OfficerFeb 02 '26Proposed Sale0.49120,00059,088Feb 02 02:31 PM
Neff R MatthewDirectorDec 01 '25Sale0.892,0001,771151,102Dec 02 04:41 PM
Neff R MatthewDirectorDec 01 '25Proposed Sale0.892,0001,771Dec 01 11:29 AM
Neff R MatthewDirectorNov 03 '25Sale1.242,0002,487153,102Nov 04 05:16 PM
Neff R MatthewDirectorOct 24 '25Option Exercise1.9410,00019,400155,102Oct 28 04:03 PM
Neff R MatthewDirectorOct 01 '25Sale1.432,0002,858145,102Oct 03 04:25 PM
Neff R MatthewDirectorSep 02 '25Sale1.672,0003,338147,102Sep 04 10:46 AM
Neff R MatthewDirectorSep 02 '25Proposed Sale1.676,00010,000Sep 02 11:24 AM
Neff R MatthewDirectorAug 01 '25Sale1.912,0003,818149,102Aug 04 04:28 PM
Neff R MatthewDirectorJul 01 '25Sale1.812,0003,621151,102Jul 03 04:30 PM
Neff R MatthewDirectorJun 02 '25Sale2.622,0005,246153,102Jun 04 04:05 PM
Neff R MatthewDirectorJun 02 '25Proposed Sale2.606,00015,600Jun 02 10:26 AM
Coelho Mary TheresaDirectorApr 01 '25Sale2.355,50012,91674,303Apr 02 04:32 PM
Coelho Mary TheresaDirectorApr 01 '25Proposed Sale2.835,50015,565Apr 01 06:33 PM
Freeman Jeffrey BrennanVP-Finance & Corp. ControllerFeb 18 '25Sale4.041,3395,41627,478Feb 20 04:34 PM
Taylor BethChief Financial OfficerFeb 18 '25Sale4.014,37017,507108,368Feb 20 04:33 PM
Sagartz John EChief Strategy OfficerFeb 18 '25Sale3.942,1138,316707,816Feb 20 04:33 PM
Leasure Robert Jr.President and CEOFeb 18 '25Sale3.8273,617281,136956,592Feb 20 04:32 PM